| Drug Name |
Tigecycline |
| Drug ID |
BADD_D02217 |
| Description |
Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005. |
| Indications and Usage |
Since glycylcyclines are similar to tetracyclines, they share many of the same side effects and contraindications as tetracyclines. These side effects may include nausea/vomiting, headache, photosensitivity, discoloration of growing teeth, and fetal damage. |
| Marketing Status |
Prescription |
| ATC Code |
J01AA12 |
| DrugBank ID |
DB00560
|
| KEGG ID |
D01079
|
| MeSH ID |
D000078304
|
| PubChem ID |
54686904
|
| TTD Drug ID |
D0G4OD
|
| NDC Product Code |
70121-1647; 0781-3481; 44657-0055; 60715-1001; 70594-035; 0008-4994; 58623-0048; 16729-364; 0008-4990; 70600-002; 63323-960; 68225-013; 60505-6098; 55150-228; 67680-002; 63415-0134; 71288-019 |
| Synonyms |
Tigecycline | TBG-MINO | 9-(tert-Butylglycylamido)minocycline | Tygacil | GAR 936 | GAR-936 | GAR936 |
